TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome

Laryngoscope

Volumn 122, Issue 5, 2012, Pages 1043-1050

  Sherman, Eric J ^a   Fisher, Susan G ^c   Kraus, Dennis H ^a   Zelefsky, Michael J ^a   Seshan, Venkatraman E ^a   Singh, Bhuvanesh ^a   Shaha, Ashok R ^a   Shah, Jatin P ^a   Wolf, Gregory T ^b   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

combined modality therapy; decision making; Laryngeal neoplasms; prognosis; speech

Indexed keywords

ALBUMIN; ALCOHOL; CISPLATIN; FLUOROURACIL; FOLINATE CALCIUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; DRINKING BEHAVIOR; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; KARNOFSKY PERFORMANCE STATUS; LARYNX CARCINOMA; LARYNX PRESERVATION; MAJOR CLINICAL STUDY; MALE; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; PHARYNX CANCER; PHARYNX CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84859889721     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23220     Document Type: Article

References (58)

1. Dropkin MJ, Malgady RG, Scott DW, Oberst MT, Strong EW,. Scaling of disfigurement and dysfunction in postoperative head and neck patients. Head Neck Surg 1983; 6: 559-570. (Pubitemid 13004342)
2. Mohide EA, Archibald SD, Tew M, Young JE, Haines T,. Postlaryngectomy quality-of-live dimensions identified by patients and health care professionals. Am J Surg 1992; 164: 619-622.
3. DeSanto LW, Olsen KD, Perry WC, Rohe DE, Keith RL,. Quality of life after surgical treatment of cancer of the larynx. Ann Otol Rhinol Laryngol 1995; 104: 763-769.
4. Lehmann W, Krebs H,. Interdisciplinary rehabilitation of the laryngectomee. Recent Results Cancer Res 1991; 121: 442-449.
5. Hassmann E, Skotnicka B,. Feasibility of supracricoid laryngectomy based on pathological examination. Eur Arch Otorhinolaryngol 1998; 255: 68-73. (Pubitemid 28143755)
6. Weinstein GS, El-Sawy MM, Ruiz C, et al. Laryngeal preservation with supracricoid partial laryngectomy results in improved quality of life when compared with total laryngectomy. Laryngoscope 2001; 111: 191-199. (Pubitemid 32142822)
7. Gilbert RW, Birt D, Shulman H, et al. Correlation of tumor volume with local control in laryngeal carcinoma treated by radiotherapy. Ann Otol Rhinol Laryngol 1987; 96: 514-518. (Pubitemid 18021380)
8. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
9. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T,. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Reasearch and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-899. (Pubitemid 26230640)
10. Terrell JE, Fisher SG, Wolf GT,. Long-term quality of life after treatment of laryngeal cancer. Arch Otolaryngol Head Neck Surg 1998; 124: 964-971. (Pubitemid 28411497)
11. Pfister DG, Bajorin D, Motzer R, et al. Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1994; 120: 89-95. (Pubitemid 24021808)
12. Maluf F, Sherman EJ, Kraus DH, et al. Long-term follow-up in patients treated with a larynx preservation approach using sequential chemotherapy and radiation therapy: the Memorial Hospital experience. Acta Oncologica Brasileira 2000; 20: 78-82.
13. Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20: 2980-2987. (Pubitemid 34728893)
14. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH,. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-1381. (Pubitemid 8108287)
15. Vikram B, Strong E, Shah J, et al. A non-looping afterloading technique for base of tongue implants: results in the first 20 patients. Int J Radiat Oncol Biol Phys 1985; 11: 1853-1855. (Pubitemid 16224028)
16. Feinstein AR, Sosin DM, Wells CK,. The Will Rogers phenomenon: stage migration and new diagnostic technology techniques as a source for misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-1608. (Pubitemid 15062653)
17. Barbera L, Groome PA, Mackillop WJ, et al. The role of computed tomography in the T classification of laryngeal carcinoma. Cancer 2001; 91: 394-407. (Pubitemid 32099242)
18. Mick R, Vokes EE, Weichselbaum RR, Panje WR,. Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. Otolaryngol Head Neck Surg 1991; 105: 62-73.
19. Piccirillo JF, Sasaki CT, Wells CK, Feinstein AR,. New clinical severity staging system for cancer of the larynx. Ann Otol Rhinol Laryngol 1994; 103: 83-92. (Pubitemid 24072265)
20. Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, Simpson JR,. Symptoms as an index of biologic behavior in head and neck cancer. Otolaryngol Head Neck Surg 1999; 120: 380-386. (Pubitemid 29135874)
21. Lassaletta L, Garcia-Pallares M, Morera E, Bernaldez R, Gavilan J,. T3 glottic cancer: oncologic results and prognostic factors. Otolaryngol Head Neck Surg 2001; 124: 556-560. (Pubitemid 33733772)
22. Franchin G, Minatel E, Gobitti C, et al. Radiation treatment of glottic squamous cell carcinoma, stage I and II: analysis of factors affecting prognosis. Int J Radiat Oncol Biol Phys 1998; 40: 541-548. (Pubitemid 28104222)
23. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck 1998; 20: 1-7.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
25. Cognetti F, Pinnaro P, Ruggeri EM, et al. Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 1989; 7: 829-837. (Pubitemid 19172455)
26. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-717.
27. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18: 385-394. (Pubitemid 30056429)
28. De Boer MF, Van den Borne B, Pruyn JF, et al. Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: results of a 6-year longitudinal study. Cancer 1998; 83: 2567-2579. (Pubitemid 29019579)
29. Himberlin C, Merol JC, Nasca S, et al. Prognostic significance of routine clinical and laboratory data in advanced head and neck cancers. Anticancer Res 1996; 16: 1005-1010. (Pubitemid 26182048)
30. Huang GW, Nong HT, Yu QS, Kinjoh K, Nakamura M, Kosugi T,. Platelet aggregation in head and neck tumors in China. Laryngoscope 1997; 107: 1142-1145. (Pubitemid 27335275)
31. Cheng SH, Jian JJ, Tsai SY, et al. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 755-762. (Pubitemid 28285951)
32. Medow MA, Weed HG, Schuller DE,. Simple predictors of survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2002; 128: 1282-1286. (Pubitemid 35403307)
33. Wolf G, Hong W, Fisher S, et al. Larynx preservation with induction chemotherapy and radiation in advanced laryngeal cancer: final results of the VA laryngeal cancer study group cooperative trial. Proc Amer Soc Clin Oncol 1993; 12: 277.
34. Spaulding MB, Fischer SG, Wolf GT,. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994; 12: 1592-1599. (Pubitemid 24244994)
35. Cox DR,. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
36. Zahalsky AJ, Sherman EJ, Kraus D, et al. A multivariate assessment of concomitant boost (CB) radiation therapy (RT) and cisplatin versus conventional RT as part of a larynx preservation (LP) strategy. Proc Am Soc Clin Oncol 2001; 20:(Abstract 898).
37. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA,. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546. (Pubitemid 12155954)
38. Begg CB, Cramer LD, Venkatraman ES, Rosai J,. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000; 19: 1997-2014. (Pubitemid 30670519)
39. Schemper M, Smith TL,. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346. (Pubitemid 26342716)
40. McNeil BJ, Weichselbaum R, Pauker SG,. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981; 305: 982-987. (Pubitemid 11026381)
41. DiNardo LJ, Kaylie DM, Isaacson J,. Current treatment practices for early laryngeal carcinoma. Otolaryngol Head Neck Surg 1999; 120: 30-37. (Pubitemid 29036316)
42. Bjordal K, Freng A, Thorvik J, Kaasa S,. Patient self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study. Eur J Cancer B Oral Oncol 1995; 31B: 235-241.
43. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-1460. (Pubitemid 20195333)
44. Spitz M,. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21: 281-288. (Pubitemid 24191586)
45. Saracci R,. The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 1987; 9: 175-193.
46. Gillison ML, Koch WM, Shah KV,. Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 1999; 11: 191-199. (Pubitemid 29229613)
47. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720. (Pubitemid 30365531)
48. Gillison ML, Lowy DR,. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489.
49. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269. (Pubitemid 351480538)
50. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
51. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420. (Pubitemid 351480511)
52. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995; 113: 408-412.
53. Gregg CM, Beals TE, McClatchy KM, Fisher SG, Wolf GT,. DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 1993; 108: 731-737. (Pubitemid 23199394)
54. Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89: 308-313. (Pubitemid 27085893)
55. Teknos TN, Cox C, Barrios MA, et al. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope 2002; 112: 844-851. (Pubitemid 34477614)
56. Staton J, Robbins KT, Newman L, Samant S, Sebelik M, Vieira F,. Factors predictive of poor functional outcome after chemoradiation for advanced laryngeal cancer. Otolaryngol Head Neck Surg 2002; 127: 43-47. (Pubitemid 41115026)
57. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886. (Pubitemid 20026073)
58. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA,. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358-366. (Pubitemid 32229380)